STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

Rhea-AI Summary
Zai Lab and Bristol Myers Squibb announce positive results from the pivotal Phase 3 KRYSTAL-12 trial evaluating KRAZATI in KRASG12C-mutated NSCLC patients. Adagrasib shows significant benefits in progression-free survival and overall response rate compared to standard chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
-
News

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Rhea-AI Summary
Bristol Myers Squibb (BMY) awards $1.8M in grants to eight organizations in Brazil, India, Thailand, and the United Kingdom to address social determinants of health (SDoH) and advance health equity. The initiative is part of a broader commitment to invest $150M in health equity by 2025. The grants aim to tackle inequities in healthcare systems by supporting organizations in underserved communities dealing with cancer and blood disorders. The company plans to expand the program based on pilot outcomes to remove systemic barriers to care and improve health outcomes globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…

Rhea-AI Summary
Bristol Myers Squibb's KRYSTAL-12 trial on KRAZATI (adagrasib) for KRASG12C-mutated NSCLC meets primary endpoint of progression-free survival, showing significant benefits over standard chemotherapy. FDA approval granted in the U.S., with positive results in Phase 2 trials for other cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
News

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease

Rhea-AI Summary
Bristol Myers Squibb (BMY) announces that the Phase 3 YELLOWSTONE trial evaluating Zeposia in Crohn’s disease did not meet its primary endpoint of clinical remission at Week 12. The safety profile was consistent with previous trials. The company plans a full evaluation of the data and will share results in the future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
-
News

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes

Rhea-AI Summary
Bristol Myers Squibb (BMY) awards $1.8M in grants to organizations in Brazil, India, Thailand, and the UK to address social determinants of health. The initiative aims to advance health equity and is part of a $150M commitment by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
-
News

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Rhea-AI Summary
Bristol Myers Squibb (BMY) presents data at ACC Annual Scientific Session on CAMZYOS® for hypertrophic cardiomyopathy, showcasing real-world evidence and safety data. The REMS Program evaluation reveals a 2.8% incidence of LVEF <50% in over 1500 patients, reinforcing the drug's safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences
News

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma

Rhea-AI Summary
Bristol Myers Squibb's Abecma (BMY) gains EC approval for treating relapsed and refractory multiple myeloma, showcasing a 51% reduction in disease progression risk. The approval signifies a significant milestone in bringing cell therapy into earlier treatment lines, offering hope to patients with options. Abecma has a well-established safety profile and has demonstrated superior efficacy over standard regimens, leading to improved progression-free survival and overall response rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none
-
News

Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Rhea-AI Summary
Bristol Myers Squibb's Opdivo plus Yervoy combo shows significant survival improvement in liver cancer trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
clinical trial
-
News

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Rhea-AI Summary
Award-winning actor Ted Danson partners with Bristol Myers Squibb for the 'SO, Have You Found It?' campaign to spotlight the resilience of individuals with moderate to severe plaque psoriasis, encouraging them to navigate their condition confidently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
News

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

Rhea-AI Summary
PureTech Health plc announces the completed acquisition of Karuna Therapeutics, Inc. by Bristol Myers Squibb for approximately $14 billion. PureTech to receive $293 million gross proceeds from its equity position in Karuna. KarXT, a potential first-in-class treatment for schizophrenia, has a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024. Bristol Myers Squibb expects the transaction to be dilutive to its non-GAAP diluted earnings per share by approximately $0.30 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
acquisition

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $57.58 as of December 23, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 115.5B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

Nasdaq:BMY

BMY Rankings

#108 Ranked by Market Cap
#715 Ranked by Dividends

BMY Stock Data

115.55B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON